MedTrace Logo

Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS

NCT06187298 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 146

Last updated 2024-01-29

No results posted yet for this study

Summary

Irritable bowel syndrome (IBS) is a prevalent, chronic functional gastrointestinal (GI) disorder, characterized by recurrent abdominal discomfort (pain) associated with altered bowel movements. IBS has a considerable negative impact on people's quality of life (QoL). There is currently no specific treatment available for IBS; most of the therapeutic management is symptomatic. Reported evidence suggest that BBR and CUR can alleviate symptoms of IBS through their multiple pharmacological effects including preventing stress-induced intestinal inflammation and visceral hypersensitivity, reducing bowel motility, and regulating intestinal permeability, gut microme and gut-brain axis.

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

A combined supplement of Berberine and Curcumin (Enterophytol® PLUS) alongside standard of care

(Enterophytol® PLUS) alongside standard of care

Sponsors & Collaborators

  • University of Liege

    collaborator OTHER

  • Liaquat University of Medical & Health Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2022-05-16
Completion
2023-12-15

Countries

  • Pakistan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06187298 on ClinicalTrials.gov